09:50 AM EST - Oncolytics Biotech Inc : Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal. “We want to thank the FDA for its very clear guidance and helping us create an efficient pathway for pelareorep in a disease that is desperate for new treatments,” said Jared Kelly, Chief Executive Officer of Oncolytics. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.02 at $1.05.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6965975253781036
